JP2020530993A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530993A5
JP2020530993A5 JP2020505194A JP2020505194A JP2020530993A5 JP 2020530993 A5 JP2020530993 A5 JP 2020530993A5 JP 2020505194 A JP2020505194 A JP 2020505194A JP 2020505194 A JP2020505194 A JP 2020505194A JP 2020530993 A5 JP2020530993 A5 JP 2020530993A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
cell
expressed
noi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530993A (ja
Filing date
Publication date
Priority claimed from GBGB1712407.4A external-priority patent/GB201712407D0/en
Priority claimed from GBGB1806372.7A external-priority patent/GB201806372D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/052204 external-priority patent/WO2019025800A1/en
Publication of JP2020530993A publication Critical patent/JP2020530993A/ja
Publication of JP2020530993A5 publication Critical patent/JP2020530993A5/ja
Priority to JP2023057340A priority Critical patent/JP2023076572A/ja
Pending legal-status Critical Current

Links

JP2020505194A 2017-08-02 2018-08-01 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 Pending JP2020530993A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023057340A JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1712407.4 2017-08-02
GBGB1712407.4A GB201712407D0 (en) 2017-08-02 2017-08-02 Cell
GB1806372.7 2018-04-19
GBGB1806372.7A GB201806372D0 (en) 2018-04-19 2018-04-19 Cell
PCT/GB2018/052204 WO2019025800A1 (en) 2017-08-02 2018-08-01 CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023057340A Division JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Publications (2)

Publication Number Publication Date
JP2020530993A JP2020530993A (ja) 2020-11-05
JP2020530993A5 true JP2020530993A5 (https=) 2021-07-26

Family

ID=63371717

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505194A Pending JP2020530993A (ja) 2017-08-02 2018-08-01 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
JP2023057340A Pending JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023057340A Pending JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Country Status (7)

Country Link
US (1) US20210130775A1 (https=)
EP (1) EP3662055A1 (https=)
JP (2) JP2020530993A (https=)
CN (1) CN111164203A (https=)
AU (1) AU2018311345A1 (https=)
CA (1) CA3071495A1 (https=)
WO (1) WO2019025800A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
CN113924103B (zh) * 2019-03-06 2025-02-14 莱蒂恩技术公司 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2021028359A1 (en) * 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
JP2022546315A (ja) * 2019-08-20 2022-11-04 センティ バイオサイエンシズ インコーポレイテッド キメラ抑制性受容体
KR20220095228A (ko) * 2019-11-06 2022-07-06 베이롤 칼리지 오브 메드신 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
CN115968300A (zh) * 2020-05-11 2023-04-14 艾宾妥斯生物公司 用于体内转导的载体和方法
GB202013466D0 (en) * 2020-08-27 2020-10-14 Inst De Medicina Molecular Joaeo Lobo Antunes Genetic construct
EP4455157A1 (en) * 2023-04-27 2024-10-30 Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps Polynuceotide for t cell specific transgene expression
WO2025226608A1 (en) * 2024-04-22 2025-10-30 The Johns Hopkins University Immunotoxin-armored immune effector cells and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US8465743B2 (en) * 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2014055657A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
DK2958943T3 (da) * 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20160296562A1 (en) * 2013-11-21 2016-10-13 Ucl Business Plc Cell
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
CN112094347A (zh) * 2014-03-05 2020-12-18 奥托路斯有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
US11385233B2 (en) * 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
KR102376244B1 (ko) * 2014-12-24 2022-03-21 오토러스 리미티드 세포
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
JP6949728B2 (ja) * 2015-05-29 2021-10-13 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
US10286092B2 (en) * 2015-08-25 2019-05-14 Ucl Business Plc Detecting a therapeutic cell
US11098283B2 (en) * 2015-08-25 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-Myb
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CA2999037A1 (en) * 2015-09-23 2017-03-30 Cytoimmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
JP7115982B2 (ja) * 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
KR102622910B1 (ko) * 2016-09-08 2024-01-10 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
JP2019535262A (ja) * 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
EP3612568B8 (en) * 2017-04-18 2021-12-08 Autolus Limited Cell
GB201707779D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
CN118147137A (zh) * 2017-05-17 2024-06-07 西雅图儿童医院（Dba西雅图儿童研究所） 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
GB201716728D0 (en) * 2017-10-12 2017-11-29 Autolus Ltd Cell
KR20200075851A (ko) * 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
GB201718697D0 (en) * 2017-11-13 2017-12-27 Autolus Ltd Cell
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
GB201807870D0 (en) * 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
GB201807862D0 (en) * 2018-05-15 2018-06-27 Ucl Business Plc Chimeric antigen receptor
AU2019269118B2 (en) * 2018-05-15 2025-02-27 Autolus Limited Chimeric antigen receptor
PL3856775T3 (pl) * 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
GB201816522D0 (en) * 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
WO2020183131A1 (en) * 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201906202D0 (en) * 2019-05-02 2019-06-19 Autolus Ltd Cell
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle

Similar Documents

Publication Publication Date Title
JP2020530993A5 (https=)
JP7219254B2 (ja) 腫瘍細胞による免疫抑制を低下させるための方法および組成物
JP7745032B2 (ja) 一本鎖および多鎖キメラポリペプチドならびにその使用方法
Labanieh et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Khan et al. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Guedan et al. Engineering and design of chimeric antigen receptors
Nabhan et al. Targeted alveolar regeneration with Frizzled-specific agonists
Dong et al. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration
Sagiv et al. NKG2D ligands mediate immunosurveillance of senescent cells
Nebral et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia
Kudo-Saito et al. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
Su et al. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs
AU2018268087B2 (en) Compositions and methods for cell targeting therapies
BR112020007576A2 (pt) composições e métodos para degradação de proteína seletiva
Ito et al. mTOR complex signaling through the SEMA4A–Plexin B2 axis is required for optimal activation and differentiation of CD8+ T cells
JP2023076572A (ja) キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
RU2017132293A (ru) Химерный белок
EP3191592A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
CN113195526B (zh) 针对过继性t细胞疗法中的突变myd88l265p蛋白表位的特异性t细胞受体
Jaeger-Ruckstuhl et al. TNIK signaling imprints CD8+ T cell memory formation early after priming
WO2024073775A2 (en) Compositions and methods for enhancing adoptive t cell therapeutics
Yi et al. L1 cell adhesion molecule induces melanoma cell motility by activation of mitogen-activated protein kinase pathways
KR20230143135A (ko) Cd19+, cd20+ 또는 cd22+ 종양 또는 b-세포 유래 자가-면역질환을 치료하기 위한 car t-세포
KR20240090127A (ko) 개선된 면역치료법을 위한 방법 및 조성물